|Bid||51.24 x 1300|
|Ask||0.00 x 3200|
|Day's Range||61.74 - 62.51|
|52 Week Range||49.96 - 70.05|
|PE Ratio (TTM)||274.76|
|Forward Dividend & Yield||1.60 (2.57%)|
|1y Target Est||N/A|
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.
AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
At an industry event Thursday, representatives from both Merck & Co. and Bristol-Myers Squibb stressed the importance of flexibility in real-estate assets.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.
Could Bristol-Myers Squibb (BMY) be the one to come out with the next Humira? Probably not, but its new drug candidate for plaque psoriasis BMS-986165 at least has a shot to come within the same ballpark. How did Humira get to be the best-selling drug of all time, and why should Bristol-Myers' new candidate dare at all compare?
It has a collaboration with Bristol-Myers Squibb (BMY) that’s targeted at cardiovascular disease. AMT-130 has received orphan drug designation in the United States and orphan medicinal product designation from the European Medicines Agency.
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Bristol-Myers Squibb Company (NYSE:BMY) as an investment opportunity by taking theRead More...
Bristol-Myers Squibb said on Wednesday its experimental drug helped reduce the severity of the most common form of psoriasis in a mid-stage trial. The study tested the drug, BMS-986165, in 267 patients with plaque psoriasis, a chronic condition that causes dry, red skin lesions covered with silvery scales. After 12 weeks, between 67 percent and 75 percent of patients given a 3-milligram dose twice daily, or a higher dose, showed a 75 percent reduction on a scale called PASI that is considered the benchmark of main goals for most psoriasis clinical trials.
AstraZeneca’s (NYSE:AZN) profits look poised to resume growing, as a number of the drug company’s new treatments are expected to be approved by regulators. While ultimately the new drugs should compensate for the lost Crestor sales, it’s too early to say when the positive outlook will be reflected in AZN stock. If these forecasts hold, and AZN stock can trade consistently above $40 per share, AstraZeneca stock could finally rally.
Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.
Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.